《大行報告》高盛將世茂服務(00873.HK)納入「確信買入」名單 首予目標價22元
高盛發表報告指,首予世茂服務(00873.HK)「買入」評級及目標價22元,此相當預測明年市盈率28倍,納其為該行「確信買入」名單。
該行指,世茂服務有兩項主要增長動力,包括併購和發展增值服務,料公司至2023年可成為中國內地十大物管公司之一。
高盛指,預期世茂服務於2021至2023年盈利年複合增長率可達35%(對比同業為31%),主因併購帶動,同時增值服務亦有快速增長,帶動公司估值提升。
該行料世茂服務於2020年至2022年每股盈利預測各為0.34元、0.5元及0.67元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.